©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 24, 2023; 14(12): 606-619
Published online Dec 24, 2023. doi: 10.5306/wjco.v14.i12.606
Published online Dec 24, 2023. doi: 10.5306/wjco.v14.i12.606
Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy
Ning Wang, Lu Pan, Yan Teng, Wen-Yu Li, School of Medicine, South China University of Technology, Guangzhou 510006, Guangdong Province, China
Fei-Li Chen, Xiao-Juan Wei, Han-Guo Guo, Xin-Miao Jiang, Ling Huang, Si-Chu Liu, Zhan-Li Liang, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China
Author contributions: The study conception and design were performed by Wang N, Chen FL, and Li WY; Data collection was performed by Wang N; All authors contributed to the data analysis and interpretation; Statistical analysis was performed by Wang N and Chen FL; The first draft of the manuscript was written by Wang N; All authors revised the manuscript.
Institutional review board statement: The study was reviewed and approved by the Guangdong Provincial People’s Hospital Institutional Review Board.
Informed consent statement: All patients provided written informed consent to participate in this study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
Corresponding author: Wen-Yu Li, Doctor, Chief Doctor, School of Medicine, South China University of Technology, No. 123 Huifu West Road, Guangzhou 510006, Guangdong Province, China. lwy80411@163.com
Received: June 1, 2023
Peer-review started: June 1, 2023
First decision: August 16, 2023
Revised: September 5, 2023
Accepted: November 17, 2023
Article in press: November 17, 2023
Published online: December 24, 2023
Processing time: 203 Days and 19.4 Hours
Peer-review started: June 1, 2023
First decision: August 16, 2023
Revised: September 5, 2023
Accepted: November 17, 2023
Article in press: November 17, 2023
Published online: December 24, 2023
Processing time: 203 Days and 19.4 Hours
Core Tip
Core Tip: Zanubrutinib combined with high-dose methotrexate provided a marked clinical response and tolerance in newly diagnosed primary central nervous system lymphoma patients. Additionally, the detection of circulating tumor DNA in cerebrospinal fluid played a significant part in disease surveillance and treatment response monitoring. However, given the small sample size and retrospective nature of this study, further research is required to validate our findings.